global leader in therapeutic ultrasound and present in the market for more than 30 years, edap tms (nasdaq: edap) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. edap tms is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. by constantly investing in research & development and partnering with internationally renowned medical research institutions, edap tms has developed a strong valuable patent portfolio based on its innovative technologies. with its complete range of robotic hifu devices, edap tms is the most innovative company in minimally-invasive treatment for localized prostate cancer. by combining the latest technologies in imaging and treatment modalities, edap tms just introduced the focal one® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing ablatherm® hifu. as a pioneer and ke
Company profile
Ticker
EDAP
Exchange
Website
CEO
Marc Oczachowski
Employees
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
EDAP stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
17 Apr 24
F-3
Shelf registration (foreign)
5 Apr 24
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Current report (foreign)
27 Mar 24
6-K
Current report (foreign)
4 Mar 24
6-K
Current report (foreign)
2 Jan 24
6-K
Current report (foreign)
7 Dec 23
6-K
Current report (foreign)
9 Nov 23
6-K
Current report (foreign)
24 Aug 23
6-K
Current report (foreign)
6 Jun 23
Transcripts
EDAP
Earnings call transcript
2023 Q4
27 Mar 24
EDAP
Earnings call transcript
2023 Q2
24 Aug 23
EDAP
Earnings call transcript
2022 Q4
30 Mar 23
EDAP
Earnings call transcript
2022 Q3
17 Nov 22
EDAP
Earnings call transcript
2022 Q2
25 Aug 22
EDAP
Earnings call transcript
2022 Q1
18 May 22
EDAP
Earnings call transcript
2021 Q4
31 Mar 22
EDAP
Earnings call transcript
2021 Q2
26 Aug 21
EDAP
Earnings call transcript
2021 Q1
12 May 21
EDAP
Earnings call transcript
2020 Q4
31 Mar 21
Latest ownership filings
SC 13G/A
Soleus Capital Master Fund, L.P.
2 Feb 24
SC 13G/A
Soleus Capital Master Fund, L.P.
14 Feb 23
SC 13G/A
MORGAN STANLEY
9 Feb 23
SC 13G/A
Soleus Capital Master Fund, L.P.
28 Sep 22
SC 13G/A
Soleus Capital Master Fund, L.P.
10 Feb 22
SC 13G
MORGAN STANLEY
10 Feb 22
SC 13G
Soleus Capital Master Fund, L.P.
28 Apr 21
SC 13G/A
Opaleye Management Inc.
12 Feb 21
SC 13G/A
Edap TMS Sa
14 Feb 20
SC 13G
Edap TMS Sa
7 Nov 19
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
52.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 41 |
Opened positions | 4 |
Closed positions | 16 |
Increased positions | 9 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 109.73 bn |
Total shares | 19.44 mm |
Total puts | 104.30 k |
Total calls | 64.30 k |
Total put/call ratio | 1.6 |
Largest owners | Shares | Value |
---|---|---|
Soleus Capital Management | 6.26 mm | $43.92 bn |
Soleus Capital Master Fund | 3.73 mm | $0.00 |
MS Morgan Stanley | 3.26 mm | $22.92 bn |
Rock Springs Capital Management | 1.36 mm | $9.55 bn |
FHI Federated Hermes Inc - Ordinary Shares | 1.01 mm | $7.12 bn |
Archon Capital Management | 961.50 k | $6.75 bn |
Driehaus Capital Management | 694.36 k | $4.87 bn |
Bruce & Co. | 553.65 k | $3.89 bn |
Apis Capital Advisors | 506.00 k | $3.55 bn |
Allspring Global Investments | 289.27 k | $2.03 bn |
News
HC Wainwright & Co. Maintains Buy on Edap TMS, Raises Price Target to $19
1 Apr 24
Edap TMS Q4 EPS $(0.15) Misses $(0.05) Estimate, Sales $21.30M Beat $19.66M Estimate
27 Mar 24
Earnings Scheduled For March 27, 2024
27 Mar 24
Earnings Outlook For Edap TMS
26 Mar 24
EDAP Announces FDA Breakthrough Device Designation for Focal One in the Treatment of Deep Infiltrating Rectal Endometriosis
4 Mar 24